The intermittent detection of KRAS mutant clones in blood of patients treated with anti-EGFR therapies, supports the concept that CRC cells possess an outstanding plasticity (Siravegna et al., 2015a). The gene discussed is KRAS; the disease is colorectal carcinoma.